SUVN-502

Pure 5-HT_6 Antagonist

Well Differentiated from Competitor Clinical Candidates

First-in-Class Triple Combination - A Promising New Approach for Symptomatic Treatment of Alzheimer's Disease

Phase 2 POC Study in USA (Ongoing)

SUVEN Life Sciences

SUVN-502: Well Differentiated Asset with First-in-Class Potential

- Pure 5-HT_6 receptor antagonist (>1200 fold selectivity over 5-HT_{2A} receptor)
- Superior profile that differentiates from competitor 5-HT_6 antagonists
- Robust efficacy in all phases of cognition (preclinical animal models)
- Potentiates the preclinical efficacy of current SOC for AD treatment
- Centrally located receptor, unlikely to potentiate AChEI mediated peripheral side effects
- No gastrointestinal side effects in aged population (Phase 1 study)
- No liver toxicity in healthy elderly subjects (Phase 1 MA study)
- No drug-drug interactions and dose limiting toxicity
- No effect of food, gender and age on pharmacokinetics
- Excellent human pharmacokinetics for once a day treatment
- Excellent margin of safety in all long term preclinical studies
- Well protected intellectual property in all major markets

SUVN-502: Key Pharmacology Results

Efficacy Pharmacology



Neurochemistry



Brain Activity



First-in-Class Triple Combination

SUVN-502 + Donepezil + Memantine

Superior to

Donepezil + Memantine

SUVN-502: Phase 2 POC Study in USA (Ongoing)

CT Identifier:	NCT02580305
Study Arms:	50 mg SUVN-502 + Donepezil + Memantine, 100 mg SUVN-502 + Donepezil + Memantine, Placebo + Donepezil + Memantine
Total Number of Subjects:	537 (179 subjects per arm)
Study Population:	Male and Female subjects, 50 to 85 years of age, with Moderate AD
Duration of Treatment:	26 weeks
Primary Outcome:	ADAS-cog 11
Secondary Outcome:	MMSE, CDR-SB, ADCS-ADL, NPI, C-SDD, C-SSRS, Safety and Tolerability

Contacts:

Venkat Jasti

Chairman & CEO

E-mail: info@suven.com

Ramakrishna Nirogi

Vice President, Discovery Research

E-mail: nvsrk@suven.com